Abstract Although anti–HLA (Human Leukocyte Antigen) donor-specific antibodies (DSAs)
are commonly measured in clinical practice and their relationship with transplant outcome is …

Rejection is a major complication following lung transplantation. Acute cellular rejection,
lymphocytic bronchiolitis, and antibody-mediated rejection (AMR) are all risk factors for the …

The generation of antibodies against donor-specific major histocompatibility complex (MHC)
antigens, a type of donor-specific antibodies (DSAs), after transplantation requires that …

Antibodies targeting human leukocyte antigen (HLA)/major histocompatibility complex
(MHC) proteins limit successful transplantation and transfusion, and their presence in blood …

Lung transplantation is the optimal treatment for selected patients with end-stage chronic
lung diseases. However, chronic lung allograft dysfunction remains the leading obstacle to …

BACKGROUND Improved understanding of lung transplant disease states is essential
because failure rates are high, often due to chronic lung allograft dysfunction. However …

The development of donor-specific antibodies (DSA) after lung transplantation is common
and results in adverse outcomes. In kidney transplantation, Belatacept has been associated …

Factors contributing to donor-specific HLA antibody (DSA) development after lung
transplantation have not been systematically evaluated. We hypothesized that the isolation …

Natural killer (NK) cells are innate lymphoid cells that have been increasingly recognised as
important in lung allograft tolerance and immune defence. These cells evolved to recognise …

Antibody-mediated rejection (AMR) has been identified as a significant form of acute
allograft dysfunction in lung transplantation. The development of consensus diagnostic …